Advertisement


Cornelis van de Velde, MD, PhD, on Rectal Cancer: A Database Update

2017 Gastrointestinal Cancers Symposium

Advertisement

Cornelis van de Velde, MD, PhD, of Leiden University Medical Center, discusses the International Watch & Wait database, established to track evidence on organ-preserving strategies in patients with rectal cancer (Abstract 521).

For More Information: www.IWWD.org



Related Videos

Pancreatic Cancer

Sarah E. Hoffe, MD, on Pancreatic Cancer and SBRT: Pros and Cons

Sarah E. Hoffe, MD, of the Moffitt Cancer Center, discusses the controversial role of radiation in the treatment of pancreatic cancer, recent advances in delivering short courses of high-dose stereotactic body radiation therapy, and how best to integrate this new modality in borderline and locally advanced disease.

Hepatobiliary Cancer

Ignacio Melero, MD, PhD, on Hepatocellular Carcinoma: Results of the CheckMate 040 Trial (Spanish Language Version)

Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses in Spanish study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).

Colorectal Cancer

Cynthia L. Sears, MD, on Colon Cancer: Keynote Lecture

Cynthia L. Sears, MD, of Johns Hopkins University School of Medicine, summarizes her keynote talk on microbes, microbiota, and colon cancer. Next-generation sequencing combined with biologic studies suggests that most colorectal cancer cases have specific microbiome associations.

Pancreatic Cancer
Hepatobiliary Cancer

Eileen M. O’Reilly, MD, on Pancreatic and Hepatobiliary Cancers: Selecting High-Impact Targets

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.

Hepatobiliary Cancer

Ignacio Melero, MD, PhD, on Hepatocellular Carcinoma: Results of the CheckMate 040 Trial

Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).

Advertisement

Advertisement




Advertisement